Feb. 2 at 5:55 PM
$ESPR The "Likely Window"
Most industry analysts now point to mid-to-late 2026 as the "sweet spot" for a deal.
The Trigger: If the upcoming Q1/Q2 2026 sales data shows a "hockey stick" growth curve following the January structural biology buzz, the board will likely face multiple bids.
Peer Perspective: Usually, when a company settles their patent lawsuits until 2040 and then a "miracle" second mechanism is discovered by independent scientists, they are essentially putting a "For Sale" sign on the front lawn.
